Biosimilars of anti-TNF-α inhibitors have become a valid and usually less expensive alternative to their originator drugs [1]. Therefore, switching from originator to biosimilar drugs is an increasingly widespread approach because of the potential cost savings. As more biosimilars become available, switching between biosimilars of the same originator will be likely.
Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis
Conti, Andrea;Bellinato, Francesco;Gisondi, Paolo
2021-01-01
Abstract
Biosimilars of anti-TNF-α inhibitors have become a valid and usually less expensive alternative to their originator drugs [1]. Therefore, switching from originator to biosimilar drugs is an increasingly widespread approach because of the potential cost savings. As more biosimilars become available, switching between biosimilars of the same originator will be likely.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Cross‑Switch from Etanercept Originator to Biosimilar SB4.pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
417.6 kB
Formato
Adobe PDF
|
417.6 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
